News | November 12, 2018

Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans Studies in Healthy Human Volunteers Reinforce Mechanism of Action Observed in Preclinical Studies EVANSTON, Ill.,...

News | November 1, 2018

Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy Top-line Data Expected Early in the First Quarter of 2019 EVANSTON, Ill., Nov. 01, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ:APTX), a clinical-stage...

News | October 24, 2018

PRINCIPIA BIOPHARMA APPOINTS DOLCA THOMAS, M.D. AS CHIEF MEDICAL OFFICER – Succession designed to lead Principia through next phase of growth as a clinical-stage company – SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) — Principia...

News | October 19, 2018

PRINCIPIA BIOPHARMA ANNOUNCES PRN1008 RECEIVES ORPHAN-DRUG DESIGNATION FROM FDA FOR TREATMENT OF IMMUNE THROMBOCYTOPENIC PURPURA SOUTH SAN FRANCISCO, Calif., Oct. 19, 2018 (GLOBE NEWSWIRE) — Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage...

News | October 16, 2018

PRINCIPIA ACHIEVES $10 MILLION IN ADDITIONAL MILESTONES RELATED TO DEVELOPMENT OF PRN2246/SAR442168 — Additional milestones achieved under the Sanofi collaboration which is focused on treating diseases of the central nervous system — SOUTH SAN FRANCISCO,...

News | October 17, 2018

CuraSen Therapeutics Announces $54.5 Million Series A Financing with Industry Veterans at Helm to Develop Drugs Targeting Novel Mechanism for the Treatment of Neurodegenerative Diseases Kathleen Sereda Glaub Appointed Executive Chair and Anthony Ford, PhD, Named Chief...